Literature DB >> 24851090

Potential effects of cannabidiol as a wake-promoting agent.

Eric Murillo-Rodríguez1, Andrea Sarro-Ramírez1, Daniel Sánchez1, Stephanie Mijangos-Moreno1, Alma Tejeda-Padrón1, Alwin Poot-Aké1, Khalil Guzmán2, Elda Pacheco-Pantoja3, Oscar Arias-Carrión4.   

Abstract

Over the last decades, the scientific interest in chemistry and pharmacology of cannabinoids has increased. Most attention has focused on ∆(9)-tetrahydrocannabinol (∆(9)-THC) as it is the psychoactive constituent of Cannabis sativa (C. sativa). However, in previous years, the focus of interest in the second plant constituent with non-psychotropic properties, cannabidiol (CBD) has been enhanced. Recently, several groups have investigated the pharmacological properties of CBD with significant findings; furthermore, this compound has raised promising pharmacological properties as a wake-inducing drug. In the current review, we will provide experimental evidence regarding the potential role of CBD as a wake-inducing drug.

Entities:  

Keywords:  Dopamine; hypothalamus; marijuana; sleep; sleepiness.

Year:  2014        PMID: 24851090      PMCID: PMC4023456          DOI: 10.2174/1570159X11666131204235805

Source DB:  PubMed          Journal:  Curr Neuropharmacol        ISSN: 1570-159X            Impact factor:   7.363


INTRODUCTION

Molecular Structure of Marijuana Derivates

Marijuana, hashish, bhang amongst others are different names given to derived-products from the plant C. sativa [1]. Among the molecules that constitute marijuana, Δ9-THC and CBD are the most significant compounds (Fig. ) [2]. Whereas Δ9-THCis the psychoactive molecule that binds to the CB1cannabinoid receptor and induces behavioral, neurochemical and molecular effects [3]; CBD does not promote psychotropic disturbances [4]. Moreover, recent evidence suggests that CBD is a compound with potential medical uses.

Biological Effects of Cannabidiol

Despite the fact that CBD does not bind to the CB1 cannabinoid receptor and lacks the psychotomimetic and other psychotropic effects, this cannabinoid modulates several biological functions. Current experimental data suggests that CBD is a potential candidate to be used as a therapeutic in specific medical treatments. For instance, it has been previously described that CBD acts as an anti-inflammatory and anxiolytic compound and modulates psychiatric disorders [5]. Furthermore, Martín-Santos et al., (2012) showed that when given orally CBD (600mg) no signs of anxiety, dysphoria, or physiological effects were observed in healthy male subjects [6]. Moreover, Das et al., (2013) reported that CBD can enhance consolidation of extinction learning in humans suggesting that this cannabinoid may have potential as an adjunct to extinction-based therapies for anxiety disorders [7]. Several studies provide more evidence that CBD possesses pharmacological potential, including anxiolytic, antipsychotic, antiemetic and anti-inflammatory properties [4b, 8]. In the following sections, this review will discuss the hypothesis that CBD modulates the sleep-wake cycle.

MODULATION OF SLEEP-WAKE CYCLE BY CANNABIDIOL

Whereas it has been well established that Δ9-THC promotes sleep [9], contradictory results on the effect of CBD on sleep were reported. For instance, Monti (1977) found a diminution in sleep after systemic administration of CBD [10], whereas Carlini and Cunha (1981) showed an improvement in sleep in insomniacs after using CBD [11]. Moreover, systemic administration of CBD (10 or 40 mg/kg) in male Wistar rats during the light period, enhanced the total percentage of sleep [12]. Further complexity has been added to the understanding of CBD pharmacology since Nicholson et al. (2004) found that 15mg of CBD administered to young adults increased wakefulness (W) during sleeping time [13]. In addition, our laboratory provided further evidence supporting the wake-inducing properties of CBD, as i.c.v. administrations of CBD (10µg/5µL) in rats during the lights-on period increased W, but decreased rapid eye movement (REM) sleep. The alertness was observed after the first hour post-injection [14]. A similar effect on sleep was observed when CBD was injected into the lateral hypothalamus [15] suggesting that CBD behaves as a wake-promoting compound. Supporting this observation, it was also found that this cannabinoid increased c-Fos expression in wake-related brain areas, such as hypothalamic nuclei as well as dorsal raphe nuclei (DRN). These findings were in concordance with previous reports [16]. Even though the mechanism of sleep modulation by CBD remains unclear, our group hypothesized that the dopamine (DA) system could be involved since it has been demonstrated that microinjections of CBD (10µg/1 or 5µL) in rats promotes an enhancement in the extracellular levels of DA [14,17]. Despite the wake-inducing effects caused by CBD, it remained the contradictory data reported by others. One possible explanation could lie in the differences described in the methodological procedures (route of administration, vehicle used, doses, subjects, etc). For example, in some reports, CBD was given systemically whereas others administered it centrally (either i.c.v or perfused directly into lateral hypothalamus). Moreover, some authors reported doses of 40mg/kg whereas others used a maximal dose of CBD 20µg/1µL. Despite the methodological differences reported, further experiments will be needed to clarify the potential mechanism of action of CBD on sleep modulation.

Putative Mechanisms of Action of Cannabidiol on Waking

Despite the lack of solid evidence concerning the role of CBD on sleep modulation, we can draw the following putative mechanism of action:

Neuroanatomical Basis

Hypothalamus.- Central administration of CBD enhances c-Fos expression in the hypothalamus [14]. Several reports suggest a key role of hypothalamus in the modulation of alertness [18]. Dorsal raphe nuclei.- Central administration of CBD enhances c-Fos expression in DRN [14]. It is known that electrophysiological activity of DRN is higher in the waking state and decreases during sleep, being virtually absent in REM sleep [19].

Neurochemical Basis

Using a microdialysis approach, DA contents collected from AcbC have been found enhanced after central administration of CBD [14, 17]. This result was further confirmed by using other experimental techniques [20].

Integrative Perspective

It is known that lesions of DA neurons reduce arousal in animal models [21], as well as in Parkinson’s disease patients that present sleep dysfunction such as excessive daytime sleepiness [22]. Therefore, we postulate that alertness induced by CBD may be associated with the increase in DA release. If CBD induces alertness via activation of neurons in the hypothalamus and promotes the enhancement in DA levels, it would suggest that the enzymatic process involved in the formation of catecholaminesmay be under the influence of CBD. Complementary experiments testing the role of CBD on the biosynthesis of catecholamines would provide us a better understanding of the phenomena. Although this hypothesis would provide scope for speculation on the mechanism of action of CBD on sleep modulation, it might give new insights regarding the role of CBD on the sleep-wake cycle mechanisms (Fig. ).

The Potential Therapeutic use of Cannabidiol on Sleep Disorders

Sleep disturbances display a range of different polysomnographic features classified as sleep disorders. According to the International Classification of Sleep Disorders (ICSD, 2001), the sleep disorders are classified into four categories [23]: Dyssomnias: Problems initiating and maintaining sleep, and also excessive sleepiness Parasomnias: Disorders of arousal, partial arousal, or sleep stage transition Sleep disorders associated with mental, neurologic, or other medical disorders Other sleep disorders: Sleep disorders not included in categories I, II or III Epidemiological data obtained from the National Sleep Foundation (NSF) Poll 2008 (USA) showed that 36% of subjects reported that they had fallen asleep while driving. Moreover, the NSF 2012 Sleep in America poll showed that pilots are most likely to report sleep-related job performance. For example, pilots (23%) admitted that sleepiness has affected their job performance. These striking data suggest a presence of general sleep disturbances and indicate the importance of exploring new therapeutic approaches to managing sleepiness. Thus, based on experimental evidence, it could be interesting to explore the potential therapeutic properties of the use of CBD to treat and manage sleepiness. The ICSD defines somnolence as sleep episodes that are present during the alertness that require mild to moderate attention. Somnolence might occur as a secondary health condition, such as side effects of medication, illicit substance use, or obstructive sleep apnea [24]. The use of CBD for different medical purposes has been recently suggested due to it improves symptoms of several disorders (for a comprehensive review see [25]).

CONCLUSION AND PERSPECTIVES

Several pieces of evidence have shown that CBD acts as a positive compound in different treatments to manage several health conditions, such as psychiatric and neurodegenerative disorders [5a, b, 8c, 26]. Thus, it could be plausible to consider the use of CBD to explore its medical properties in somnolence. The current review highlights the pharmacological evidence on the effects of CBD on sleep modulation and provides a putative mechanism of action. For a better understanding of the molecular and neuroanatomical mechanism by which CBD regulates sleep, this subject should be further investigated.
  51 in total

1.  Sleep-related violence: does the polysomnogram help establish the diagnosis?

Authors: 
Journal:  Sleep Med       Date:  2000-10-01       Impact factor: 3.492

2.  Dynamics of neuron activity in the lateral preoptic area of the hypothalamus during the sleep-waking cycle.

Authors:  N V Suntsova; O Yu Dergacheva
Journal:  Neurosci Behav Physiol       Date:  2003-09

Review 3.  Basic sleep mechanisms: an integrative review.

Authors:  Eric Murillo-Rodriguez; Oscar Arias-Carrion; Abraham Zavala-Garcia; Andrea Sarro-Ramirez; Salvador Huitron-Resendiz; Gloria Arankowsky-Sandoval
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2012-03

Review 4.  Circadian and sleep disorders in Parkinson's disease.

Authors:  Aleksandar Videnovic; Diego Golombek
Journal:  Exp Neurol       Date:  2012-08-23       Impact factor: 5.330

5.  The effect of lesions of catecholamine-containing neurons upon monoamine content of the brain and EEG and behavioral waking in the cat.

Authors:  B E Jones; P Bobillier; C Pin; M Jouvet
Journal:  Brain Res       Date:  1973-08-17       Impact factor: 3.252

6.  Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum.

Authors:  Pablo Pandolfo; Vasco Silveirinha; Alexandre dos Santos-Rodrigues; Laurent Venance; Catherine Ledent; Reinaldo N Takahashi; Rodrigo A Cunha; Attila Köfalvi
Journal:  Eur J Pharmacol       Date:  2011-01-23       Impact factor: 4.432

7.  Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats.

Authors:  Eric Murillo-Rodríguez; Diana Millán-Aldaco; Marcela Palomero-Rivero; Raphael Mechoulam; René Drucker-Colín
Journal:  FEBS Lett       Date:  2006-07-10       Impact factor: 4.124

8.  The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent.

Authors:  Eric Murillo-Rodríguez; Diana Millán-Aldaco; Marcela Palomero-Rivero; Raphael Mechoulam; René Drucker-Colín
Journal:  Behav Neurosci       Date:  2008-12       Impact factor: 1.912

9.  Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease.

Authors:  Sebastian Paus; Hans Michael Brecht; Jürgen Köster; Gert Seeger; Thomas Klockgether; Ullrich Wüllner
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

10.  Effects of electrolytic lesion of hypothalamic paraventricular nucleus and its related areas on the sleep waking cycle in the cat.

Authors:  M Sallanon; K Kitahama; C Buda; M Puymartin; P H Luppi; M Jouvet
Journal:  Arch Ital Biol       Date:  1987-10       Impact factor: 1.000

View more
  11 in total

Review 1.  Cannabis, Cannabinoids, and Sleep: a Review of the Literature.

Authors:  Kimberly A Babson; James Sottile; Danielle Morabito
Journal:  Curr Psychiatry Rep       Date:  2017-04       Impact factor: 5.285

2.  Systemic Injections of Cannabidiol Enhance Acetylcholine Levels from Basal Forebrain in Rats.

Authors:  Eric Murillo-Rodríguez; Gloria Arankowsky-Sandoval; Nuno Barbosa Rocha; Rodrigo Peniche-Amante; André Barciela Veras; Sérgio Machado; Henning Budde
Journal:  Neurochem Res       Date:  2018-06-06       Impact factor: 3.996

3.  Sleep-wake cycle disturbances and NeuN-altered expression in adult rats after cannabidiol treatments during adolescence.

Authors:  Eric Murillo-Rodríguez; Diana Millán-Aldaco; Dorotea Cicconcelli; Valentina Giorgetti; Gloria Arankowsky-Sandoval; Jocelyne Alcaraz-Silva; Claudio Imperatori; Sérgio Machado; Henning Budde; Pablo Torterolo
Journal:  Psychopharmacology (Berl)       Date:  2021-02-26       Impact factor: 4.530

4.  Natural Cannabinoids as Templates for Sleep Disturbances Treatments.

Authors:  Eric Murillo-Rodríguez; Sérgio Machado; Claudio Imperatori; Tetsuya Yamamoto; Henning Budde
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids.

Authors:  Michelle Sexton; Jose M Garcia; Aminah Jatoi; Carey S Clark; Mark S Wallace
Journal:  J Natl Cancer Inst Monogr       Date:  2021-11-28

Review 6.  The Effects of Cannabinoids on Sleep.

Authors:  Bhanu Prakash Kolla; Lisa Hayes; Chaun Cox; Lindy Eatwell; Mark Deyo-Svendsen; Meghna P Mansukhani
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec

Review 7.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

8.  Dose-dependent cannabis use, depressive symptoms, and FAAH genotype predict sleep quality in emerging adults: a pilot study.

Authors:  Kristin E Maple; Kymberly A McDaniel; Skyler G Shollenbarger; Krista M Lisdahl
Journal:  Am J Drug Alcohol Abuse       Date:  2016-04-13       Impact factor: 3.829

Review 9.  Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders.

Authors:  Malvika Kaul; Phyllis C Zee; Ashima S Sahni
Journal:  Neurotherapeutics       Date:  2021-02-12       Impact factor: 7.620

Review 10.  Industrial Hemp (Cannabis sativa subsp. sativa) as an Emerging Source for Value-Added Functional Food Ingredients and Nutraceuticals.

Authors:  H P Vasantha Rupasinghe; Amy Davis; Shanthanu K Kumar; Beth Murray; Valtcho D Zheljazkov
Journal:  Molecules       Date:  2020-09-07       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.